Peptide API supplier for Europe: sourcing from India, step by step

Who buys peptides from India, and what each needs

The requirements depend on what the peptide will be used for. Once a peptide becomes the active substance of a medicine or of a clinical-trial product, the full GMP chain described below applies. For laboratory research it does not, but the buyer still needs reliable identity, purity and documentation.

Buyer	Typical use	Grade	Key requirements
Pharmaceutical manufacturers and generic developers	Active substance of an authorised medicine; development batches for a generic or hybrid application	GMP API	Written confirmation, EU GMP Part II, ASMF or full Module 3.2.S data, supplier audit and QP declaration (covered in this guide)
Biotech and drug-development companies	Investigational medicinal products for clinical trials	GMP API	Clinical Trials Regulation (EU) No 536/2014, GMP for investigational medicinal products (Delegated Regulation (EU) 2017/1569) and certification of each batch by a Qualified Person
CDMOs, CMOs and fill-finish companies	API sourced for a client’s product, or a client’s API taken into vials	GMP API or client-supplied	The client’s specification and quality agreement; EU GMP Part I and Annex 1 for sterile filling
Veterinary medicine manufacturers	Active substance of a veterinary medicine	GMP API	Regulation (EU) 2019/6 and its own GMP and import rules for active substances
Universities, hospital and biomedical research institutes	In-vitro and preclinical laboratory research	Research grade (RUO)	Certificate of analysis with identity (mass spectrometry) and purity (HPLC), counter-ion and peptide content where needed, and an end-use statement
CROs and analytical laboratories	Method development, impurity identification, in-house working standards	Research grade or custom	Full characterisation data; official pharmacopoeial reference standards still come from EDQM or USP
Diagnostics and assay developers	Peptides as antigens, calibrators or controls	Research grade or custom	Supplier qualification by the device manufacturer under the IVD Regulation (EU) 2017/746, and lot-to-lot consistency
Research-peptide brands and distributors	Resale to laboratories, often in lyophilised vials	Research grade (RUO)	Batch certificates of analysis, “research use only, not for human or veterinary use” labelling, and compliance with national rules on what may be sold and how

Research-grade material cannot be upgraded later: a peptide bought for laboratory research cannot become the active substance of a medicine or a clinical-trial product. Tell us the end use in your first enquiry so we quote the right grade and documents.

What an EU pharmaceutical buyer needs in place

Four obligations sit between an Indian API manufacturer and an EU marketing authorisation. They fall on different parties, and a missing one stops the supply chain regardless of how good the material is.

Requirement	Legal basis	Who holds it	What to ask the supplier for
GMP at least equivalent to EU GMP	Art 46b(2)(a), Directive 2001/83/EC; EU GMP Part II / ICH Q7	API manufacturer	Site master file, GMP inspection history, agreement to audits
Written confirmation	Art 46b(2)(b)	Issued by CDSCO to the manufacturer	Current confirmation naming the site and the active substance
Active substance documentation	Module 3.2.S of the dossier; ASMF guideline; CEP procedure	MA applicant, with the ASMF holder	ASMF Applicant’s Part and letter of access, or full 3.2.S data
QP declaration based on audit	Art 46(f); EMA QP declaration template	QP of each EU manufacturing authorisation holder using the API	Audit access and a quality agreement

The EU importer of the active substance also has to be registered with its national competent authority at least 60 days before starting the activity (Article 52a), and registrations are published in EudraGMDP.

Written confirmation for active substances made in India

Since 2 July 2013, Article 46b(2) of Directive 2001/83/EC has allowed active substances to be imported only if they are made to GMP standards at least equivalent to the Union’s and are accompanied by a written confirmation from the competent authority of the exporting country. The confirmation states that the exporting authority applies equivalent GMP standards, that the plant is subject to regular, strict and transparent controls including repeated and unannounced inspections, and that non-compliance findings will be reported to the Union without delay. The Commission publishes a template for it.

Countries assessed as equivalent are listed under Article 111b and need no written confirmation. The current list (Implementing Decision 2012/715/EU as amended) has nine entries: Australia, Brazil, Canada, Israel, Japan, the Republic of Korea, Switzerland, Taiwan and the United States. India is not on it, so APIs made in India need a written confirmation from the Central Drugs Standard Control Organisation (CDSCO).

Article 46b(4) provides a narrow waiver: exceptionally, and where needed to ensure availability of medicines, a Member State that has inspected the plant may waive the confirmation for no longer than the validity of its GMP certificate. It is not a routine sourcing route.

Practical checks: the confirmation must name the specific manufacturing site and the specific active substance, and it must be valid on the date of import. A written confirmation is a statement about the exporting authority’s oversight; it is not a substitute for your own audit.

GMP: EU GMP Part II and ICH Q7

EU GMP Part II sets the basic requirements for active substances used as starting materials. It began as Annex 18 to the EU GMP Guide in 2000, reflecting the EU’s adoption of ICH Q7. For a synthetic peptide, GMP applies from the introduction of the API starting materials, and EMA’s synthetic peptides guideline states that ICH Q11 principles on starting material selection apply. Protected L-amino acid derivatives are generally acceptable as starting materials; short peptide fragments may be acceptable when justified.

Filling a peptide into vials for a medicinal product is a finished-product step and falls under EU GMP Part I and, for sterile products, Annex 1. That distinction matters if you plan to combine API supply with fill-finish or lyophilisation by the same partner.

Choosing the dossier route: full data, ASMF or CEP

Route	When it is available	What the MA applicant sees	Notes
Full data in Module 3.2.S	Always	Everything	Requires the manufacturer to share confidential process details with you
Active Substance Master File (ASMF)	Any active substance	The Applicant’s Part only	The Restricted Part (process know-how) goes straight to the authority; a letter of access links the ASMF to your application
Certificate of Suitability (CEP)	Only where a Ph. Eur. monograph exists	The CEP and its annexes	EDQM assesses the data; the CEP replaces most of 3.2.S

The ASMF procedure is set out in EMA guideline CHMP/QWP/227/02 Rev 4. CEPs are issued by the EDQM against European Pharmacopoeia monographs, so they cannot exist for a substance without one. A search of the EDQM certification database for semaglutide returned no record on 11 October 2026, which leaves the ASMF or full data as the routes for semaglutide today.

The QP declaration and supplier audits

Article 46(f) of Directive 2001/83/EC requires every manufacturing authorisation holder to use only active substances manufactured in accordance with GMP and distributed in accordance with GDP, and to verify this by audits at the manufacturing and distribution sites. The Qualified Person confirms it in the QP declaration, using the EMA template, which records whether the audit was carried out on site, when, and by whom. Third-party audits are permitted under the conditions set out in EMA’s guidance and Q&A.

For buyers, the consequence is simple: an API supplier that will not accept audits by you or your contracted auditor cannot be used in an EU medicinal product. Ask about audit access at the first conversation, not after technical evaluation.

Synthetic peptides: what EMA expects

EMA’s guideline on the development and manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025) was adopted in December 2025 and came into effect on 1 June 2026. Its main points for API buyers:

• Synthetic peptides are fully or partly excluded from ICH Q3A/B, Q6A/B and M7, so peptide-specific expectations apply instead.
• Peptide-related impurities follow the Ph. Eur. general monograph thresholds: reported above 0.1%, identified above 0.5% and qualified above 1.0%.
• The specification typically covers identity, purity, high-molecular-weight impurities such as aggregates, assay, counter-ion content, residual TFA, water, residual solvents, endotoxins and microbiological purity.
• For a synthetic version of a recombinant reference product, the biosimilar pathway is not available. EMA expects a full comparison of the peptide-related impurity profile at 0.1–0.5% against the EU reference product, with a quantification limit of 0.1%.

For semaglutide specifically, EMA has published a draft product-specific bioequivalence guidance (EMA/106257/2026, consultation to 31 October 2026) stating that semaglutide substance sameness should be shown before a bioequivalence study. See our article on peptide API impurities and specifications for the analytical detail.

United Kingdom and Switzerland

Great Britain kept the written-confirmation model after leaving the EU. Regulation 450 of the Human Medicines Regulations 2012 requires a written confirmation from the exporting country’s competent authority unless the manufacturer is in an approved country. The MHRA list of approved countries for active substances covers the EU/EEA, Australia, Brazil, Israel, Japan, the Republic of Korea, Switzerland and the USA. India is not on it, so a CDSCO written confirmation is needed for GB imports as well.

Switzerland is on the EU’s Article 111b list, so Swiss-made APIs need no written confirmation for EU import. Swiss rules on importing active substances into Switzerland are set by Swissmedic; confirm the current requirements with Swissmedic or your Swiss regulatory contact.

Semaglutide in Europe: the patent timeline

Semaglutide’s compound protection in Europe runs to 2031 through supplementary protection certificates, according to Novo Nordisk’s 2025 annual report. Commercial supply of generic semaglutide into EU markets therefore waits for expiry, but development and regulatory work for a generic application is covered in principle by the Bolar provision of Article 10(6) of Directive 2001/83/EC. National implementations differ, particularly on whether third-party API supply for that work is covered, so take patent advice for each market. Our article on semaglutide patent expiry by country sets out the dates.

Where Winhycare Pharma fits

• Peptide APIs: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide and BPC-157, supplied B2B to licensed pharmaceutical manufacturers and developers with a Certificate of Analysis, and CTD Module 3 documentation support for Semaglutide.
• Peptide CRDMO services: process and analytical development and technology transfer for your own peptide programme.
• Peptide lyophilisation and vial filling: peptides and biosimilars lyophilised and filled into vials through our manufacturing partner, starting with engineering or pilot batches.
• Research peptides and custom peptide synthesis: 16 research peptides at >99% purity and custom sequences for universities, research institutes, CROs, diagnostics developers and distributors, supplied for research use only and not as GMP API.

We will tell you plainly which documents exist today for your molecule and target market, and which would need to be generated, before you commit to an audit. Peptide APIs are supplied to licensed manufacturers and developers. Research-grade peptides are supplied for research use only and cannot be qualified as the active substance of a medicinal product.

How to start

1. Send an enquiry with the molecule, quantity, target market, intended use (laboratory research, development, clinical or commercial) and the documents your QP, quality or regulatory team needs.
2. Sign a mutual NDA.
3. Review technical and quality documentation and complete your supplier questionnaire.
4. Evaluate samples, or run a pilot for lyophilisation projects.
5. Audit the site with your QA team or a contracted auditor.
6. Agree the quality agreement and supply terms.